Science AI Journal
Medicine · Research topic

Open research questions in Heart Failure Treatment and Management

1,009 gap statements mined from Heart Failure Treatment and Management papers in our 7.9M-paper local library, which holds 5,253 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Heart Failure Treatment and Management? See the ranked Medicine journals.

What the literature leaves open

  • Based on the follow-up, especially in the outpatient setting, it is reasonably achievable to be able to up titrate BB to goal in that timeframe, acknowledging the lack of data surrounding “goal dosing BB.

    Safety of Inpatient and Outpatient Beta Blocker Initiation in Pediatric Heart Failure · 2026 · DOI

  • Future research should focus on optimizing treatment strategies, tailoring medical therapies, and addressing the underrepresentation of women in clinical trials to ensure equitable care for all LVHF patients. Further studies incorporating detailed echocardiographic and medication data are warranted to confirm and extend these findings.

    Sex-specific differences in disease severity and outcomes in left ventricular heart failure: a nationwide cohort study · 2026 · DOI

  • This study has several limitations that need to be acknowledged. Furthermore, CRP was assessed only once during index hospitalization and therefore changes in inflammatory activity over time or after discharge could not be evaluated. It remains uncertain whether CRP is a causal mediator of adverse outcomes or primarily a marker of increased risk in HF.

    Even mild elevations of C-reactive protein levels predict long-term prognosis in heart failure with mildly reduced ejection fraction · 2026 · DOI

  • Urinary sodium may represent a useful marker to identify higher-risk phenotypes and generate hypotheses that warrant further investigation in AHF.

    Urinary sodium and right ventricular function in acute heart failure · 2026 · DOI

  • Despite these well-established associations, previous studies have not investigated the mechanisms by which RV dysfunction leads to adverse outcomes in AHF.

    Urinary sodium and right ventricular function in acute heart failure · 2026 · DOI

  • While the remarkable observed difference may be attributable to chance, it nonetheless does warrant further investigation. These findings warrant further investigation and confirmation to clarify the sex-specific differences in response to diuretic therapy in patients with acute HF.

    Effects of natriuresis-guided diuretic therapy in men and women with acute heart failure: insights from PUSH-AHF · 2026 · DOI

  • In the broader spectrum of rapidly evolving heart-failure therapeutics, including pharmacological and device-based strategies, the clinical value of interatrial shunting remains uncertain.

    Interatrial Shunt Devices in Heart Failure: A Therapy in Search of the Right Patient · 2026 · DOI

  • Renal function did not account for the interaction, which persisted with and without the eGFR in the model and after adjustment for diuretic dose and MRA use. Coronary anatomy had not been assessed in a third of patients, more often in women, and hence, ischemic etiology may be underascertained; discharge therapy was not included in the prognostic model.

    Sex differences in clinical phenotypes and prognostic associations in acute heart failure · 2026 · DOI

  • These results, along with the positive effects observed in HF self-care behaviors and other health outcomes, provide good evidence that a full-scale RCT to more definitively examine the efficacy of the iCardia4HF intervention in patients with HF is warranted.

    Patient-Centered mHealth Intervention to Improve Self-Care in Patients With Chronic Heart Failure: Phase 1 Randomized Controlled Trial · 2025 · DOI

  • Cardiorenal syndrome (CRS) remains a major clinical challenge due to the complex and bidirectional interplay between cardiac and renal dysfunction, which conventional biomarkers like creatinine and natriuretic peptides fail to fully capture.

    Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome · 2025 · DOI

  • In studies performed in acute HF, the mean CA-125 at discharge is variable, ranging from 38 to 100 U/mL; however, no data on the percentage of patients admitted with acute HF and normal CA-125 are found in these articles.

    Predictive Factors of Non-Elevation of Carcinoembryonic Antigen 125 in Acute Heart Failure · 2025 · DOI

  • In contrast to previous studies focusing on chronic heart failure or exacerbations, our findings provide evidence for the prognostic relevance of NT-proBNP in an as-yet underexplored setting.

    NT-proBNP in Acute De Novo Heart Failure: A Key Biomarker for Predicting Myocardial Recovery—COMFE Registry · 2025 · DOI

  • Although numerous prognostic models have been developed for HF, their routine implementation in clinical practice remains limited. For these models to become more reliable and widely adopted, several key steps are required.

    Prognostic Models in Heart Failure: Hope or Hype? · 2025 · DOI

  • Further research is needed to clarify the implications of supranormal EF on outcomes, particularly through sex-stratified analyses, as the current findings remain inconclusive. In this respect, the association between the sex of the patients and the presence of diabetes remains uncertain, with contradictory results in the literature.

    Impact of Sex on Rehospitalization Rates and Mortality of Patients with Heart Failure with Preserved Ejection Fraction: Differences Between an Analysis Stratified by Sex and a Global Analysis · 2025 · DOI

  • As the field of heart failure management evolves, several future directions are anticipated for HF-DMPs: Integration of artificial intelligence (AI): AI-powered risk prediction models and ECG interpretation tools may enable real-time, personalized interventions. Expansion of virtual care: enhanced telemonitoring and remote titration clinics will increase access, especially for rural and underserved populations.

    Advancing Heart Failure Care Through Disease Management Programs: A Comprehensive Framework to Improve Outcomes · 2025 · DOI

  • Secondly, the generalizability of results is limited as it used the method of convenience sampling in public hospital in Athens, which is not representative of all Greek HF patients and their caregivers.

    Quality of Life in Heart Failure Patients: The Effect of Anxiety and Depression (Patient–Caregiver) and Caregivers’ Quality of Life · 2025 · DOI

  • From a more practical point of view, one cannot forget that the future increase in remote monitoring technologies may encounter several potential challenges such as the difficulties elderly patients may have in the daily use of telemedicine platforms and digital devices.

    MEMS Technology in Cardiology: Advancements and Applications in Heart Failure Management Focusing on the CardioMEMS Device · 2024 · DOI

  • Finally, future research is required to improve the methodology of measuring algorithmic bias and to test more fairness definitions and measures (eg, calibration parity) through an operational lens. However, these metrics have limited interpretability and are insufficient to inform mechanisms of bias or guide intervention planning.

    Evaluating Algorithmic Bias in 30-Day Hospital Readmission Models: Retrospective Analysis · 2024 · DOI

  • The fact that it measures visuospatial and language functions, which have been under explored in these patients, was also a factor in the selection of the test.

    Assessment of cognitive function in patients with heart failure: impact of clinical and sociodemographic factors · 2026 · DOI

  • Over the last four decades, the management of cardiovascular, renal, and metabolic disease has evolved from an organ-specific approach to an integrated cardiorenal–metabolic paradigm.

    Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 2 · 2026 · DOI

  • ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes?

    Efficacy of sacubitril/valsartan on improving clinical symptoms in patients with acute myocardial infarction complicated with heart failure: a retrospective study · 2025 · DOI

  • Novel Pharmacological and Device Therapies Advances in the management of AHF are being actively explored through ongoing clinical trials regarding novel pharmacological and device-based therapies. A significant focus lies in novel pharmacological agents targeting unique pathways of myocardial injury, inflammation, and fibrosis.

    Transition to Advanced Heart Failure: From Identification to Improving Prognosis · 2025 · DOI

  • These findings confirm HF as a major driver of adverse prognosis in CKD, adding time-to-event information that has been underreported in prior studies.

    CaReMe-CKD-HF–Epidemiology of Heart Failure in Chronic Kidney Disease: A Retrospective Analysis of Routine Administrative Data from a German Hospital Network · 2025 · DOI

  • The four pillars of HFrEF therapy (ARNi or RAAS inhibitors, β-blockers, MRAs, and SGLT2 inhibitors) retain their cardiovascular benefit across the CKD stages in which they have been tested, whereas the evidence for kidney protection differs by class: it is strongest for SGLT2 inhibitors, which have dedicated kidney-outcome trials, rests on secondary analyses for ARNi and MRAs, and is lacking for β-blockers, whose…

    Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia · 2026 · DOI

  • Investigate the mechanisms underlying the postprandial suppression of MR-proANP, - Examine the relationship between postprandial NP responses and cardiovascular outcomes, - Study the effects of different meal compositions on cardiometabolic…

    Meal-induced changes in cardiometabolic peptides in the context of acute cardiovascular diseases and glucose metabolism · 2026 · DOI

Most-cited papers in Heart Failure Treatment and Management

Most recent work

Find a gap in your own Heart Failure Treatment and Management sub-topic

This page shows what the Heart Failure Treatment and Management literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) Future research should focus on optimizing treatment strategies, tailoring medical therapies, and addressing the underrepresentation of women in clinical trials to ensure equitable care for all LVHF patients (“Sex-specific differences in disease severity and outcomes in left ventricular…”, 2026); (2) Although numerous prognostic models have been developed for HF, their routine implementation in clinical practice remains limited (“Prognostic Models in Heart Failure: Hope or Hype?”, 2025); (3) Further research is needed to clarify the implications of supranormal EF on outcomes, particularly through sex-stratified analyses, as the current findings remain inconclusive (“Impact of Sex on Rehospitalization Rates and Mortality of Patients with Heart…”, 2025); (4) Future research is required to improve the methodology of measuring algorithmic bias and to test more fairness definitions and measures (eg, calibration parity) through an operational lens (“Evaluating Algorithmic Bias in 30-Day Hospital Readmission Models:…”, 2024). 1,009 gap statements have been mined from Heart Failure Treatment and Management papers in our 7.9M-paper local library, which holds 5,253 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.